Clinical Trials

2,000 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT04293562 2026-02-24

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Phase 3 Recruiting

1,186 enrolled

Phase 2 Active not recruiting

Leukemia, Myeloid, Acute

NCT03672539 2026-02-20

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

50 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03737955 2026-01-28

Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia

36 enrolled

Phase EARLY_PHASE1 Completed

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

NCT03568994 2026-01-27

ATACC AML

26 enrolled

Leukemia, Myeloid, Acute

NCT06448013 2025-12-15

A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

Phase 1 Recruiting

22 enrolled

Leukemia, Myeloid, Acute

NCT05955261 2025-12-09

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Phase 2 Suspended

70 enrolled

Leukemia, Myeloid, Acute

NCT03589729 2025-11-20

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

MyeloidOther hematologic neoplasmSarcoma

100 enrolled

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT03900949 2025-10-28

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

21 enrolled

Leukemia, Myeloid, Acute

NCT04385290 2025-09-08

MOSAIC

Phase 1/2 Recruiting

214 enrolled

Leukemia, Myeloid, Acute

NCT04849910 2025-07-29

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

Phase 1/2 Terminated

67 enrolled

Phase 1 Active not recruiting

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05716009 2025-05-06

GO-TAG

36 enrolled

Leukemia, Myeloid, Acute

NCT04070768 2025-05-04

Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

18 enrolled 15 charts

Recurrence, Leukemia, Myeloid, Acute

NCT04050280 2025-05-01

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

39 enrolled

Phase 1 Not yet recruiting

Recurrence, Leukemia, Myeloid, Acute

NCT05662904 2025-03-14

GALAXY33

12 enrolled

Leukemia, Myeloid, Acute

NCT03839446 2025-02-20

Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy

16 enrolled 13 charts

Phase 2 Active not recruiting

Leukemia, Myeloid, Acute

NCT05599360 2024-12-02

Vyxeos for Induction of Low- or Intermediate-risk.

20 enrolled

Leukemia, Myeloid, Acute

NCT05904106 2024-12-02

VINCENT

146 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04168502 2024-11-08

Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

Phase 3 Recruiting

414 enrolled

Leukemia, Myeloid, Acute

NCT04207190 2024-11-01

Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

24 enrolled

Phase 2 Active not recruiting

Leukemia, Myeloid, Acute

NCT03374332 2024-02-08

Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

11 enrolled

Recurrence, Leukemia, Myeloid, Acute, Disease Progression

NCT02473146 2024-02-02

ALFA1401

Phase 2/3 Completed

225 enrolled

Leukemia, Myeloid, Acute

NCT03904251 2023-11-18

CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Phase 1 Terminated

13 enrolled

Leukemia, Leukemia, Myeloid, Acute

NCT02117297 2023-10-26

SCT Plus Immune Therapy in Average Risk AML/MDS

26 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02221310 2023-10-26

Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS

25 enrolled

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03390296 2023-09-05

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

50 enrolled 13 charts

Leukemia, Myeloid, Acute

NCT03531918 2023-08-30

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm

66 enrolled 18 charts

Leukemia, Myeloid, Acute

NCT00005962 2023-06-22

Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Acute

NCT00049517 2023-06-15

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia

Phase 3 Completed

657 enrolled 8 charts

Leukemia, Leukemia, Myeloid, Acute

NCT04173585 2023-03-27

TEAM

50 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT03878927 2023-03-10

CPX GO

Phase 1 Terminated

11 enrolled

Leukemia, Myeloid, Acute

NCT03848754 2022-06-30

Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

14 enrolled

Leukemia, Myeloid, Acute

NCT04326439 2022-06-15

AflacLL1901 (CHOA-AML)

Phase 2 Terminated

8 enrolled 12 charts

Leukemia, Myeloid, Acute

NCT02724163 2021-10-08

Myechild01

Phase 3 Recruiting

700 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04337138 2021-08-09

A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World

Completed

32 enrolled 18 charts

Leukemia, Myeloid, Acute

NCT01020539 2021-08-06

AML/MDS/JMML

18 enrolled

1,070 enrolled 18 charts 2 FDA

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Juvenile

NCT00372593 2021-03-24

Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 3 Completed

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

NCT02272478 2020-01-23

AML18

Phase 2/3 Unknown

1,600 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00895934 2019-05-23

Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML

52 enrolled 12 charts

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT00766116 2019-02-18

Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)

50 enrolled 6 charts

Leukemia, Myeloid, Acute

NCT01548911 2018-07-02

Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia

Phase 2 Withdrawn

Congenital Abnormalities, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

NCT01869803 2018-03-02

Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia

Approved for marketing

Congenital Abnormalities, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

NCT03287128 2018-01-24

MYLOR

Unknown

300 enrolled

Leukemia, Myeloid, Acute

NCT00673153 2017-06-01

Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Phase 2 Terminated

31 enrolled 11 charts